Alembic Pharma Gets US FDA Tentative Approval for Acalabrutinib Capsules
Alembic Pharmaceuticals gained 1.19 percent to Rs 559 following the tentative approval of its Acalabrutinib capsules from the US Food and Drug Administration (USFDA). Calquence capsules, 100 mg, from AstraZeneca UK (AstraZeneca), the reference listed drug product (RLD), is the therapeutic equivalent of the approved ANDA. Acalabrutinib capsules are indicated for the treatment of adult […]
Continue Reading